Only any grade rash was more frequent in patients administered CTLA-4 inhibitor combined with PD-1/-L1 inhibitor, in comparison to CTLA-4 inhibitor monotherapy [any grade pruritus RR:0.98 (95% CI 0.80-1.19, p = 0.81) (Figure 6E), any grade rash RR:1.37 (95% CI 1.07-1.74, p = 0.01) (Figure 6F)]. The gene discussed is CTLA4; the disease is Pruritus.